Sonia Guzzo

Sonia Guzzo

Auto-generated profile, based on publicly available information

Sonia Guzzo

Department of Urology, IRCCS Policlinico San Donato, University of Milan, Milan, Italy

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2022 in Medicina
Verified
Journal Article
Open access
PDF file
ABAlessandra Brescacin
Alessandra Brescacin
SISamuele Iesari
Samuele Iesari
SGSonia Guzzo
Sonia Guzzo
CACarlo Alfieri
Carlo Alfieri
RDRuggero Darisi
Ruggero Darisi
Evaldo FaviEvaldo Favi
Evaldo Favi
Allograft vesicoureteral reflux (VUR) is a leading urological complication of kidney transplantation. Despite the relatively high incidence, there is a lack of consensus regarding VUR risk factors, impact on renal function, and management. Dialysis vintage and atrophic bladder have been recognized as the most relevant recipient-related determinants of post-transplant VUR, whilst possible relationships with sex, age, and ureteral implantation technique remain debated. Clinical manifestations vary from an asymptomatic condition to persistent or recurrent urinary tract infections (UTIs). Voiding cystourethrography is widely accepted as the gold standard diagnostic modality, and the reflux is generally graded following the International Reflux Study Committee Scale. Long-term transplant outcomes of recipients with asymptomatic grade I-III VUR are yet to be clarified. On the contrary, available data suggest that symptomatic grade IV-V VUR may lead to progressive allograft dysfunction and premature transplant loss. Therapeutic options include watchful waiting, prolonged antibiotic suppression, sub-mucosal endoscopic injection of dextranomer/hyaluronic acid copolymer at the site of the ureteral anastomosis, and surgery. Indication for specific treatments depends on recipient’s characteristics (age, frailty, compliance with antibiotics), renal function (serum creatinine concentration < 2.5 vs. ≥ 2.5 mg/dL), severity of UTIs, and VUR grading (grade I-III vs. IV-V). Current evidence supporting surgical referral over more conservative strategies is weak. Therefore, a tailored approach should be preferred. Properly designed studies, with adequate sample size and follow-up, are warranted to clarify those unresolved issues.

3 December 2018 in Urologia Journal
Verified
Journal Article
Closed access
ABAndrea Benelli
Andrea Benelli
VVVirginia Varca
Virginia Varca
CVChiara Vaccaro
Chiara Vaccaro
SGSonia Guzzo
Sonia Guzzo
MNMarta Nicola
Marta Nicola
FNFranca Di Nuovo
Franca Di Nuovo
Introduction: Bladder mucosa is anatomically covered by urothelial epithelium. The replacement of the urothelium with stratified squamous cells is defined as squamous metaplasia which can be keratinizing or non-keratinizing. Clinically, it is also known as leukoplakia or keratinizing cystitis of the bladder. Although several etiologic factors have been proposed such as chronic inflammation, irritative stimuli and infection, its pathogenesis is not clearly understood. The natural history of squamous metaplasia and clinical treatment are controversial. Many authors consider squamous metaplasia as a premalignant lesion, so it is fundamental to find an effective treatment to reduce the risk of developing bladder squamous carcinoma. Case description: We report our management of a 58-year-old man with histological evidence of keratinizing squamous metaplasia and severe lower urinary tract symptoms. After repeated transurethral resections, the patient was treated with intravesical instillation of hyaluronic acid showing the regression of the lesion with an improvement of macroscopic appearance followed by the resolution of clinical symptoms. Conclusion: The therapeutic management of keratinizing squamous metaplasia is controversial, and currently no effective medical therapy is available for its treatment. Actually, patients undergo transurethral resections and a multidisciplinary approach is required to avoid cystectomy. Annual cystoscopy with multiple biopsies should be performed to determine the presence of dysplasia. Moreover, the therapeutic treatment with hyaluronic acid instillations could be the starting point and the gold standard in the follow-up of our patient. However, at present, further studies are required to formulate an adequate policy for therapeutic management of this unusual lesion of the bladder mucosa.

4 December 2024 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
LCLuca Carmignani
Luca Carmignani
SGSonia Guzzo
Sonia Guzzo
ABAndrea Baudo
Andrea Baudo
SNSebastiano Nazzani
Sebastiano Nazzani
EBEdoardo Bonacina
Edoardo Bonacina
CVCarlo De Vincentiis
Carlo De Vincentiis

4 March 2020
Verified
Book Chapter
Open access
PDF file
BABenelli Andrea
Benelli Andrea
VCVaccaro Chiara
Vaccaro Chiara
GSGuzzo Sonia
Guzzo Sonia
VVVarca Virginia
Varca Virginia
GAGregori Andrea
Gregori Andrea
Despite its limitations, ultrasound-guided biopsy is still the “gold standard” for the diagnosis of prostate cancer (PCa). Multiparametric magnetic resonance imaging (mp-MRI) plays an increasingly important role in patients with prior negative biopsy; several studies report an improved clinically significant prostate cancer (Cs PCa) detection rate for MRI-targeted biopsy compared to the standard biopsy. There are currently three techniques for the MRI-targeted biopsy: the cognitive registration, the software-assisted fusion registration, and the in-bore biopsy. The best MRI-targeted biopsy technique is still a matter of debate in literature; however, MRI/TRUS fusion-guided biopsy is often described as the most accurate and cost-effective approach; we describe the technique and its results.

23 June 2020 in Research Square
Verified
Preprint
Open access
PDF file
OBOskar Blezien
Oskar Blezien
CSClaudia Signorini
Claudia Signorini
SGSonia Guzzo
Sonia Guzzo
CVChiara Vaccaro
Chiara Vaccaro
FMFilippo Molinari
Filippo Molinari
LCLuca Carmignani
Luca Carmignani
Purpose To demonstrate safety of a new internal protocol for patients and health workers adopted for elective urologic surgical activity during COVID-19 pandemic.Methods From March 9 to April 24, 2020 we have retrospectively evaluated 62 patients who underwent elective surgery in the urology department of IRCCS Policlinico San Donato which became a COVID-hospital. We identified non-deferrable patients that needed to be treated within one month. All patients followed a dedicated pathway from the day-hospital till the discharge. Clinical data, nasopharyngeal swabs, chest X-ray, type of anaesthesia, surgical procedure and days of hospitalization were collected. All patients were interviewed 14 days after surgery to check any Covid-related complications.Results The population included 48 (77.42%) men and 14 (22.58%) women, aged between 17 and 88 years old. We performed sixty-four (64) preoperative screenings and two (2) patients were excluded. 47 (75.81%) patients underwent oncological procedures while 15 (24.19%) patients underwent non-oncological surgery. The average hospitalization time was 2.39±2.21 days.After at least 14 postoperative days (25.00±10.35 days), we interviewed all patients to check their conditions. No patients showed symptoms related to COVID-19, except for 2 (3.23%) who manifested coryza, 28 and 35 days after discharge respectively. Neither patients nor hospital workers developed COVID-19 infection.Conclusion The duration of pandemic period is undefined; therefore, our protocol could be considered a good model for every type of surgery and its application could ensure a continuous treatment for non-deferrable conditions, in a safe way for both the patients and health workers.